Study of Investigational Drug in Osteoporosis
Information source: Merck
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Postmenopausal Osteoporosis
Intervention: MK-0217, alendronate sodium/Duration of Treatment: 3 months (Drug); Comparator: placebo / Duration of Treatment: 3 months (Drug)
Phase: Phase 3
Status: Active, not recruiting
Sponsored by: Merck Official(s) and/or principal investigator(s):
Medical Monitor, Study Director, Affiliation: Unaffiliated
Summary
The purpose of this study is to evaluate the efficacy and safety of an investigational drug
in postmenopausal women with osteoporosis.
Clinical Details
Official title: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Persistence of the Effect of Oral Monthly Ibandronate on Bone Reception in Postmenopausal Women in Osteoporosis
Study design: Randomized, Double-Blind, Safety/Efficacy Study
Primary outcome: Biochemical markers of bone reception (CTxI and NTx/Cr)
Secondary outcome: Safety and tolerability
Eligibility
Minimum age: 50 Years.
Maximum age: N/A.
Gender(s): Female.
Criteria:
Inclusion Criteria:
- Postmenopausal women with osteoporosis
Locations and Contacts
Call for International Site Information, Horsham, Pennsylvania 19044, United States
Additional Information
Starting date: January 2005
Last updated: May 17, 2006
|
